Company intelligence / Profile preview

Adocia

Ownership: Private
Employees: ~78
Development stage: Other

Overview

Adocia focuses on developing innovative formulations of insulins and other metabolic hormones. It has partnered several products, including BioChaperone Lispro and Combo, and is exploring new technologies for cell therapy and oral delivery.

Therapeutic areas: Endocrinology
Modalities: Therapeutic proteins and peptides
Industry: Biotech

Drug pipeline

17 assets

BC LisPram

16 more assets in the full pipeline.

Partnerships

Tonghua Dongbao Pharmaceutical Co., Ltd. (for BioChaperone Lispro and Combo in Asia)Sanofi (exclusive negotiation rights for M1Pram)

Beyond the preview

Go deeper on Adocia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adocia.